Trial Profile
An Open-Label, Randomized, Two-period Crossover Study To Compare Relative Bioavailability of Two Formulations of Moroctocog Alfa (Af-cc) In Subjects With Moderately Severe Or Severe Hemophilia A (FVIII:C </=2%)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Moroctocog alfa (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Sponsors Pfizer
- 16 Apr 2015 New trial record